^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

LXF821

i
Other names: CART-EGFRvIII T cells, LXF821
Associations
Company:
Novartis, University of Pennsylvania
Drug class:
EGFRvIII-targeted CAR-T immunotherapy
Associations
1year
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab remodels the tumor microenvironment in de novo glioblastoma (SNO 2023)
Here, we conducted a phase I trial to study the safety and tolerability of CART-EGFRvIII cells administered concomitantly with the PD-1 inhibitor pembrolizumab in patients with newly diagnosed, EGFRvIII+ GBM (n=7). Together, these findings suggest that the combination of CAR T cells and PD-1 inhibition in GBM is safe and biologically active but, given the lack of efficacy, also indicate a need to consider alternative immunotherapeutic strategies. ClinicalTrials.gov registration: NCT03726515.
Combination therapy • CAR T-Cell Therapy
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • LXF821
1year
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab remodels the tumor microenvironment in de novo glioblastoma (SNO 2023)
Here, we conducted a phase I trial to study the safety and tolerability of CART-EGFRvIII cells administered concomitantly with the PD-1 inhibitor pembrolizumab in patients with newly diagnosed, EGFRvIII+ GBM (n=7). Together, these findings suggest that the combination of CAR T cells and PD-1 inhibition in GBM is safe and biologically active but, given the lack of efficacy, also indicate a need to consider alternative immunotherapeutic strategies. ClinicalTrials.gov registration: NCT03726515.
Combination therapy • CAR T-Cell Therapy
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • LXF821
almost2years
Small-molecule toosendanin reverses macrophage-mediated immunosuppression to overcome glioblastoma resistance to immunotherapy. (PubMed, Sci Transl Med)
Furthermore, TSN treatment sensitized GBM to Egfrviii chimeric antigen receptor (CAR) T cell therapy. These findings suggest that TSN may serve as a therapeutic compound that blocks tumor immunosuppression and circumvents tumor resistance to T cell-based immunotherapy in GBM and other solid tumors that warrants further investigation.
Journal
|
LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase)
|
LXF821
over3years
CART-EGFRvIII + Pembrolizumab in GBM (clinicaltrials.gov)
P1, N=7, Completed, University of Pennsylvania | Active, not recruiting --> Completed | Trial completion date: Dec 2035 --> Feb 2021 | Trial primary completion date: Aug 2035 --> Feb 2021
Clinical • Trial completion • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
EGFR (Epidermal growth factor receptor) • MGMT (6-O-methylguanine-DNA methyltransferase) • TERT (Telomerase Reverse Transcriptase)
|
EGFR amplification • MGMT promoter methylation • TERT mutation • EGFRvIII expression • TERT promoter mutation
|
Keytruda (pembrolizumab) • LXF821
almost4years
CART-EGFRvIII + Pembrolizumab in GBM (clinicaltrials.gov)
P1, N=7, Active, not recruiting, University of Pennsylvania | Trial completion date: Dec 2034 --> Dec 2035 | Trial primary completion date: Dec 2020 --> Aug 2035
Clinical • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
EGFR (Epidermal growth factor receptor) • MGMT (6-O-methylguanine-DNA methyltransferase) • TERT (Telomerase Reverse Transcriptase)
|
EGFR amplification • MGMT promoter methylation • TERT mutation • EGFRvIII expression • TERT promoter mutation
|
Keytruda (pembrolizumab) • LXF821
over4years
CART-EGFRvIII + Pembrolizumab in GBM (clinicaltrials.gov)
P1, N=7, Recruiting, University of Pennsylvania | Active, not recruiting --> Recruiting
Clinical • Enrollment open • CAR T-Cell Therapy
|
EGFR (Epidermal growth factor receptor) • MGMT (6-O-methylguanine-DNA methyltransferase) • TERT (Telomerase Reverse Transcriptase)
|
EGFR amplification • MGMT promoter methylation • TERT mutation • EGFRvIII expression • TERT promoter mutation
|
Keytruda (pembrolizumab) • LXF821